Curium to take radiopharma company Lantheus private in $8 billion deal

In a major transaction for the radiopharmaceutical sector, the closely held nuclear medicine company Curium has struck a deal to acquire Lantheus Holdings Inc. This acquisition, valued at a substantial figure of about $8 billion, will result in Lantheus, a publicly traded radiopharma company, being taken private under Curium's ownership.

Curium acquisition deal

• ▪Curium has struck a deal to acquire Lantheus Holdings Inc.
• ▪The transaction is valued at approximately $8 billion
• ▪The acquisition will result in Lantheus Holdings Inc. being taken private

Lantheus company background

• ▪Lantheus Holdings Inc. is a radiopharma company
• ▪Curium is described as a closely held nuclear medicine company